Luu Quynh Phuong, Dean Jonathan, Do Trinh Thi Diem, Carr Michael J, Dunford Linda, Coughlan Suzie, Connell Jeff, Nguyen Hien Tran, Hall William W, Nguyen Thi Lan Anh
Ireland Vietnam Blood-Borne Virus Initiative, Dublin, Ireland.
AIDS Res Hum Retroviruses. 2012 Oct;28(10):1344-8. doi: 10.1089/AID.2011.0396. Epub 2012 Mar 9.
In Vietnam, where an estimated 280,000 people will be HIV-positive by 2012, recommended antiretroviral regimens do not include more recently developed therapeutics, such as Integrase inhibitors (INI) and coreceptor antagonists. This study examined HIV-1 coreceptor tropism and INI drug resistance profiles, in parallel with CCR5 genotypes, in a cohort of 60 HIV-positive individuals from different regions of Vietnam. No evidence of INI resistance was detected. Some 40% of individuals had X4-tropic HIV-1, making them unsuitable for treatment with CCR5 antagonists. We identified a novel CCR5 variant-S272P-along with other, previously reported variants: G106R, C178R, W153C, R223Q, and S336I. Interestingly, CCR5 variants known to affect HIV-1 infectivity were observed only in individuals harboring X4-tropic virus. Together, this study presents valuable baseline information on HIV-1 INI resistance, coreceptor tropism, and CCR5 variants in HIV-positive individuals in Vietnam. This should help inform policy on the future use of novel antiretrovirals in Vietnam.
在越南,预计到2012年将有28万人感染艾滋病毒,推荐的抗逆转录病毒疗法不包括最近研发的治疗药物,如整合酶抑制剂(INI)和共受体拮抗剂。本研究在来自越南不同地区的60名艾滋病毒阳性个体队列中,同时检测了HIV-1共受体嗜性和INI耐药谱以及CCR5基因型。未检测到INI耐药的证据。约40%的个体感染了X4嗜性HIV-1,这使得他们不适合使用CCR5拮抗剂进行治疗。我们鉴定出一种新的CCR5变体——S272P,以及其他先前报道的变体:G106R、C178R、W153C、R223Q和S336I。有趣的是,已知影响HIV-1感染性的CCR5变体仅在携带X4嗜性病毒的个体中观察到。总之,本研究提供了关于越南艾滋病毒阳性个体中HIV-1 INI耐药性、共受体嗜性和CCR5变体的宝贵基线信息。这应有助于为越南未来使用新型抗逆转录病毒药物的政策提供参考。